vs
美世（MERC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是美世的1.7倍（$772.1M vs $449.5M），Revvity净利率更高（12.7% vs -68.7%，领先81.4%），Revvity同比增速更快（5.9% vs -8.0%），Revvity自由现金流更多（$161.8M vs $32.0M），过去两年Revvity的营收复合增速更高（9.0% vs -9.9%）
美世是1945年成立的美国咨询公司，为全球专业服务集团威达信的四大运营子公司之一，总部位于纽约，在43个国家设有办事处，业务覆盖130个国家，主要为客户提供人力资源与金融咨询服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MERC vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.7倍
$449.5M
营收增速更快
RVTY
高出13.8%
-8.0%
净利率更高
RVTY
高出81.4%
-68.7%
自由现金流更多
RVTY
多$129.8M
$32.0M
两年增速更快
RVTY
近两年复合增速
-9.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $449.5M | $772.1M |
| 净利润 | $-308.7M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | -62.0% | 14.5% |
| 净利率 | -68.7% | 12.7% |
| 营收同比 | -8.0% | 5.9% |
| 净利润同比 | -1947.7% | 3.9% |
| 每股收益（稀释后） | $-4.61 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MERCRVTY
| Q4 25 | $449.5M | $772.1M | ||
| Q3 25 | $458.1M | $698.9M | ||
| Q2 25 | $453.5M | $720.3M | ||
| Q1 25 | $507.0M | $664.8M | ||
| Q4 24 | $488.4M | $729.4M | ||
| Q3 24 | $502.1M | $684.0M | ||
| Q2 24 | $499.4M | $691.7M | ||
| Q1 24 | $553.4M | $649.9M |
净利润MERCRVTY
| Q4 25 | $-308.7M | $98.4M | ||
| Q3 25 | $-80.8M | $46.7M | ||
| Q2 25 | $-86.1M | $53.9M | ||
| Q1 25 | $-22.3M | $42.2M | ||
| Q4 24 | $16.7M | $94.6M | ||
| Q3 24 | $-17.6M | $94.4M | ||
| Q2 24 | $-67.6M | $55.4M | ||
| Q1 24 | $-16.7M | $26.0M |
毛利率MERCRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率MERCRVTY
| Q4 25 | -62.0% | 14.5% | ||
| Q3 25 | -14.8% | 11.7% | ||
| Q2 25 | -12.9% | 12.6% | ||
| Q1 25 | 1.3% | 10.9% | ||
| Q4 24 | 10.3% | 16.3% | ||
| Q3 24 | 1.8% | 14.3% | ||
| Q2 24 | -8.8% | 12.4% | ||
| Q1 24 | -0.1% | 6.8% |
净利率MERCRVTY
| Q4 25 | -68.7% | 12.7% | ||
| Q3 25 | -17.6% | 6.7% | ||
| Q2 25 | -19.0% | 7.5% | ||
| Q1 25 | -4.4% | 6.4% | ||
| Q4 24 | 3.4% | 13.0% | ||
| Q3 24 | -3.5% | 13.8% | ||
| Q2 24 | -13.5% | 8.0% | ||
| Q1 24 | -3.0% | 4.0% |
每股收益（稀释后）MERCRVTY
| Q4 25 | $-4.61 | $0.86 | ||
| Q3 25 | $-1.21 | $0.40 | ||
| Q2 25 | $-1.29 | $0.46 | ||
| Q1 25 | $-0.33 | $0.35 | ||
| Q4 24 | $0.25 | $0.77 | ||
| Q3 24 | $-0.26 | $0.77 | ||
| Q2 24 | $-1.01 | $0.45 | ||
| Q1 24 | $-0.25 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $186.8M | $919.9M |
| 总债务越低越好 | $1.6B | — |
| 股东权益账面价值 | $68.1M | $7.3B |
| 总资产 | $2.0B | $12.2B |
| 负债/权益比越低杠杆越低 | 23.58× | — |
8季度趋势，按日历期对齐
现金及短期投资MERCRVTY
| Q4 25 | $186.8M | $919.9M | ||
| Q3 25 | $98.1M | $931.4M | ||
| Q2 25 | $146.5M | $991.8M | ||
| Q1 25 | $181.5M | $1.1B | ||
| Q4 24 | $184.9M | $1.2B | ||
| Q3 24 | $239.0M | $1.2B | ||
| Q2 24 | $263.2M | $2.0B | ||
| Q1 24 | $274.3M | $1.7B |
总债务MERCRVTY
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | $1.6B | — |
股东权益MERCRVTY
| Q4 25 | $68.1M | $7.3B | ||
| Q3 25 | $359.5M | $7.4B | ||
| Q2 25 | $446.5M | $7.6B | ||
| Q1 25 | $437.4M | $7.6B | ||
| Q4 24 | $429.8M | $7.7B | ||
| Q3 24 | $516.8M | $7.9B | ||
| Q2 24 | $487.7M | $7.9B | ||
| Q1 24 | $573.6M | $7.8B |
总资产MERCRVTY
| Q4 25 | $2.0B | $12.2B | ||
| Q3 25 | $2.3B | $12.1B | ||
| Q2 25 | $2.4B | $12.4B | ||
| Q1 25 | $2.3B | $12.4B | ||
| Q4 24 | $2.3B | $12.4B | ||
| Q3 24 | $2.5B | $12.8B | ||
| Q2 24 | $2.5B | $13.4B | ||
| Q1 24 | $2.6B | $13.4B |
负债/权益比MERCRVTY
| Q4 25 | 23.58× | — | ||
| Q3 25 | 4.30× | — | ||
| Q2 25 | 3.42× | — | ||
| Q1 25 | 3.44× | — | ||
| Q4 24 | 3.43× | — | ||
| Q3 24 | 3.09× | — | ||
| Q2 24 | 3.22× | — | ||
| Q1 24 | 2.82× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $46.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $32.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 7.1% | 21.0% |
| 资本支出强度资本支出/营收 | 3.1% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-80.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流MERCRVTY
| Q4 25 | $46.2M | $182.0M | ||
| Q3 25 | $-30.1M | $138.5M | ||
| Q2 25 | $-4.5M | $134.3M | ||
| Q1 25 | $-3.0M | $128.2M | ||
| Q4 24 | $71.2M | $174.2M | ||
| Q3 24 | $-13.9M | $147.9M | ||
| Q2 24 | $62.2M | $158.6M | ||
| Q1 24 | $-29.2M | $147.6M |
自由现金流MERCRVTY
| Q4 25 | $32.0M | $161.8M | ||
| Q3 25 | $-60.1M | $120.0M | ||
| Q2 25 | $-28.9M | $115.5M | ||
| Q1 25 | $-23.1M | $112.2M | ||
| Q4 24 | $50.4M | $149.8M | ||
| Q3 24 | $-41.2M | $125.6M | ||
| Q2 24 | $44.3M | $136.6M | ||
| Q1 24 | $-47.7M | $129.7M |
自由现金流率MERCRVTY
| Q4 25 | 7.1% | 21.0% | ||
| Q3 25 | -13.1% | 17.2% | ||
| Q2 25 | -6.4% | 16.0% | ||
| Q1 25 | -4.6% | 16.9% | ||
| Q4 24 | 10.3% | 20.5% | ||
| Q3 24 | -8.2% | 18.4% | ||
| Q2 24 | 8.9% | 19.7% | ||
| Q1 24 | -8.6% | 20.0% |
资本支出强度MERCRVTY
| Q4 25 | 3.1% | 2.6% | ||
| Q3 25 | 6.6% | 2.6% | ||
| Q2 25 | 5.4% | 2.6% | ||
| Q1 25 | 4.0% | 2.4% | ||
| Q4 24 | 4.2% | 3.4% | ||
| Q3 24 | 5.4% | 3.3% | ||
| Q2 24 | 3.6% | 3.2% | ||
| Q1 24 | 3.3% | 2.7% |
现金转化率MERCRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 4.26× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MERC
| Other | $215.3M | 48% |
| Solid Wood | $110.2M | 25% |
| Lumber | $54.9M | 12% |
| Pallets | $23.7M | 5% |
| Energyandchemicals | $18.7M | 4% |
| Manufactured Products | $14.1M | 3% |
| Biofuels | $10.0M | 2% |
| Wood Residuals | $2.6M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
